{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:55:30Z","timestamp":1786650930142,"version":"build-2736575974"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asian J Androl"],"published-print":{"date-parts":[[2014]]},"DOI":"10.4103\/1008-682x.126400","type":"journal-article","created":{"date-parts":[[2014,4,30]],"date-time":"2014-04-30T07:53:01Z","timestamp":1398844381000},"page":"359","source":"Crossref","is-referenced-by-count":18,"title":["Heat shock and other apoptosis-related proteins as therapeutic targets in prostate cancer"],"prefix":"10.4103","volume":"16","author":[{"given":"NoahM","family":"Hahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costantine","family":"Albany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1008-682X.126400-1","first-page":"11","volume-title":"Cancer statistics, 2013","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"key-10.4103\/1008-682X.126400-2","first-page":"646","volume-title":"Hallmarks of cancer: the next generation","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"key-10.4103\/1008-682X.126400-3","first-page":"6116","volume-title":"Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy","author":"Yoshino","year":"2006","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.126400-4","first-page":"3585","volume-title":"Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02","author":"Khor","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.126400-5","first-page":"6595","volume-title":"Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer","author":"Rocchi","year":"2004","journal-title":"Cancer Res"},{"key":"key-10.4103\/1008-682X.126400-6","first-page":"79","volume-title":"Targeting the apoptosis pathway in prostate cancer","author":"Zielinski","year":"2013","journal-title":"Cancer J"},{"key":"key-10.4103\/1008-682X.126400-7","first-page":"743","volume-title":"Heat shock proteins: essential proteins for apoptosis regulation","author":"Lanneau","year":"2008","journal-title":"J Cell Mol Med"},{"key":"key-10.4103\/1008-682X.126400-8","first-page":"2731","volume-title":"Targeting heat shock proteins in prostate cancer","author":"Hessenkemper","year":"2013","journal-title":"Curr Med Chem"},{"key":"key-10.4103\/1008-682X.126400-9","first-page":"275","volume-title":"Targeting heat shock proteins in cancer","author":"Jego","year":"2013","journal-title":"Cancer Lett"},{"key":"key-10.4103\/1008-682X.126400-10","first-page":"10455","volume-title":"Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity","author":"Zoubeidi","year":"2007","journal-title":"Cancer Res"},{"key":"key-10.4103\/1008-682X.126400-11","first-page":"49","volume-title":"Hsp27 protects mitochondria of thermotolerant cells against apoptotic stimuli","author":"Samali","year":"2001","journal-title":"Cell Stress Chaperones"},{"key":"key-10.4103\/1008-682X.126400-12","first-page":"816","volume-title":"Hsp27 as a negative regulator of cytochrome C release","author":"Paul","year":"2002","journal-title":"Mol Cell Biol"},{"key":"key-10.4103\/1008-682X.126400-13","first-page":"327","volume-title":"Effect of the heat shock protein HSP27 on androgen receptor expression and function in prostate cancer cells","author":"Stope","year":"2012","journal-title":"World J Urol"},{"key":"key-10.4103\/1008-682X.126400-14","first-page":"2547","volume-title":"Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models","author":"Miyake","year":"2000","journal-title":"Cancer Res"},{"key":"key-10.4103\/1008-682X.126400-15","first-page":"1707","volume-title":"Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer","author":"Steinberg","year":"1997","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.126400-16","first-page":"427","volume-title":"Clusterin","author":"Jones","year":"2002","journal-title":"Int J Biochem Cell Biol"},{"key":"key-10.4103\/1008-682X.126400-17","first-page":"252","volume-title":"The role of stress proteins in prostate cancer","author":"So","year":"2007","journal-title":"Curr Genomics"},{"key":"key-10.4103\/1008-682X.126400-18","first-page":"909","volume-title":"Clusterin inhibits apoptosis by interacting with activated Bax","author":"Zhang","year":"2005","journal-title":"Nat Cell Biol"},{"key":"key-10.4103\/1008-682X.126400-19","unstructured":"OncoGenex Pharmaceuticals announces final results from Phase 1 Trial evaluating OGX-427 as a treatment for solid tumors. 2010; Available from: http:\/\/files.shareholder.com\/downloads\/...OncoGenex_Pharmaceuticals.pdf."},{"key":"key-10.4103\/1008-682X.126400-20","first-page":"4514","volume-title":"A randomized Phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC)","author":"Chi","year":"2012","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.126400-21","first-page":"1287","volume-title":"A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2\u2032-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer","author":"Chi","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"key-10.4103\/1008-682X.126400-22","first-page":"4247","volume-title":"Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer","author":"Chi","year":"2010","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.126400-23","first-page":"5765","volume-title":"Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c","author":"Saad","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.126400-24","first-page":"211","volume-title":"Hsp90: still a viable target in prostate cancer","author":"Centenera","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"key-10.4103\/1008-682X.126400-25","first-page":"8324\u22128","volume-title":"Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation","author":"Whitesell","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.4103\/1008-682X.126400-26","first-page":"2639","volume-title":"Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol","author":"Sharma","year":"1998","journal-title":"Oncogene"},{"key":"key-10.4103\/1008-682X.126400-27","first-page":"986","volume-title":"17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2\/neu and inhibits the growth of prostate cancer xenografts","author":"Solit","year":"2002","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.126400-28","first-page":"7940","volume-title":"A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer","author":"Heath","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.126400-29","first-page":"1561","volume-title":"A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors","author":"Pacey","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.126400-30","first-page":"626","volume-title":"Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer","author":"Oh","year":"2011","journal-title":"Urology"},{"key":"key-10.4103\/1008-682X.126400-31","first-page":"3671","volume-title":"First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors","author":"Sessa","year":"2013","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.126400-32","first-page":"522","volume-title":"The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer","author":"Graham","year":"2012","journal-title":"Cancer Sci"},{"key":"key-10.4103\/1008-682X.126400-33","first-page":"Abstract 2433","volume-title":"In vitro and in vivo antitumor activity of the next generation HSP90 inhibitor, AT13387, in both hormone-sensitive and castration-resistant prostate cancer models","author":"Ferraldeschi","year":"2013","journal-title":"Cancer Res"},{"key":"key-10.4103\/1008-682X.126400-34","first-page":"A3028","volume-title":"First-in-human phase I study: results of a second-generation non-ansamycin heat shock protein 90 (HSP90) inhibitor AT13387 in refractory solid tumors","author":"Mahadevan","year":"2012","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.126400-35","first-page":"152","volume-title":"A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies","author":"Goldman","year":"2013","journal-title":"BMC Cancer"},{"key":"key-10.4103\/1008-682X.126400-36","first-page":"A3051","volume-title":"A phase I doseescalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: updated report","author":"Cho","year":"2011","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.126400-37","first-page":"A5085","volume-title":"Antonarakis, et al. Phase II trial of single-agent ganetespib (STA-9090), a heat shock protein 90 (Hsp90) inhibitor in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel-based chemotherapy: results of a Prostate Cancer Clinical Trials Consortium (PCCTC) study","author":"Elisabeth","year":"2013","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.126400-38","first-page":"1\u22126","volume-title":"Bcl-2 and the regulation of programmed cell death","author":"Reed","year":"1994","journal-title":"J Cell Biol"},{"key":"key-10.4103\/1008-682X.126400-39","first-page":"1264\u22129","volume-title":"Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer","author":"Sternberg","year":"2009","journal-title":"Ann Oncol"},{"key":"key-10.4103\/1008-682X.126400-40","first-page":"1803","volume-title":"Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer","author":"Sonpavde","year":"2012","journal-title":"Ann Oncol"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:24:41Z","timestamp":1786649081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1008-682X.126400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"alternative-id":["126400"],"URL":"https:\/\/doi.org\/10.4103\/1008-682x.126400","relation":{},"ISSN":["1008-682X"],"issn-type":[{"value":"1008-682X","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]}}}